Literature DB >> 8284074

Fluconazole-resistant Candida in AIDS patients. Report of two cases.

G S Heinic1, D A Stevens, D Greenspan, L A MacPhail, C L Dodd, S Stringari, W M Strull, H Hollander.   

Abstract

Oropharyngeal candidiasis develops in up to 95% of patients with acquired immunodeficiency syndrome. Oral fluconazole is frequently prescribed for persons who are human immunodeficiency virus-seropositive as initial or suppressive therapy for oropharyngeal and esophageal candidiasis or as suppressive therapy for cryptococcal meningitis. We report two cases of oropharyngeal candidiasis, caused by Candida albicans, which developed in two patients with acquired immunodeficiency syndrome who had taken fluconazole for extended periods. In addition to the clinical resistance we observed, isolates of the organism appeared to be resistant in vitro to fluconazole and ketoconazole.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8284074     DOI: 10.1016/0030-4220(93)90039-7

Source DB:  PubMed          Journal:  Oral Surg Oral Med Oral Pathol        ISSN: 0030-4220


  9 in total

1.  Treatment of murine disseminated candidiasis with L-743,872.

Authors:  J R Graybill; L K Najvar; M F Luther; A W Fothergill
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

Review 2.  Susceptibility testing of fungi: current status of correlation of in vitro data with clinical outcome.

Authors:  M A Ghannoum; J H Rex; J N Galgiani
Journal:  J Clin Microbiol       Date:  1996-03       Impact factor: 5.948

3.  Yeasts and fluconazole susceptibility in the Philippines.

Authors:  G S Bulmer; M L Marquez; L Co-Barcelona; R A Fromtling
Journal:  Mycopathologia       Date:  1999       Impact factor: 2.574

4.  Clinical correlates of antifungal macrodilution susceptibility test results for non-AIDS patients with severe Candida infections treated with fluconazole.

Authors:  S C Lee; C P Fung; J S Huang; C J Tsai; K S Chen; H Y Chen; N Lee; L C See; W B Shieh
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

Review 5.  Resistance of Candida species to fluconazole.

Authors:  J H Rex; M G Rinaldi; M A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

6.  Molecular cloning and characterization of a novel gene of Candida albicans, CDR1, conferring multiple resistance to drugs and antifungals.

Authors:  R Prasad; P De Wergifosse; A Goffeau; E Balzi
Journal:  Curr Genet       Date:  1995-03       Impact factor: 3.886

Review 7.  Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients.

Authors:  K L Goa; L B Barradell
Journal:  Drugs       Date:  1995-10       Impact factor: 9.546

Review 8.  Oral candidiasis.

Authors:  A Akpan; R Morgan
Journal:  Postgrad Med J       Date:  2002-08       Impact factor: 2.401

9.  A study of antifungal drug sensitivity of Candida isolated from human immunodeficiency virus infected patients in Chennai, South India.

Authors:  Nadeem Jeddy; K Ranganathan; Uma Devi; Elizabeth Joshua
Journal:  J Oral Maxillofac Pathol       Date:  2011-05
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.